Bronchogen Peptide Research in 2026: Molecular Identity, Evidence And Quality Standards

Nov 16, 2026 Leave a message

Introduction

Short synthetic peptides continue to attract research interest as pharmacological tools and biological response modifiers. Bronchogen peptide powder is one such tetrapeptide discussed in peptide-research communities. As with many research-grade peptides distributed through specialty suppliers, public information about Bronchogen is fragmented: the reported amino acid sequence is not consistent across sources, chemical-database identifiers are not uniformly assigned, and published evidence is largely preclinical.

This review summarizes what is established about Bronchogen's molecular identity, the current research evidence, and the analytical verification steps B2B buyers should require before sourcing. It is written as a 2026 research-and-quality perspective, not as a product announcement.

What Is Bronchogen?

Bronchogen is a short synthetic peptide described in the literature as a tetrapeptide. Its reported composition is four amino acids, with nominal molecular parameters as follows:

Property Nominal value
Reported sequence (commercial database record) Ala-Glu-Asp-Leu (AEDL) - ChemicalBook CBNumber CB93358086
Reported sequence (peer-reviewed study) Ala-Asp-Glu-Leu (ADEL) - Monaselidze et al., 2011
Molecular formula (either sequence, theoretical) C₁₈H₃₀N₄O₉
Molecular weight (theoretical) Approximately 446.46 g/mol
CAS identifier PubChem lists 857267-12-0 as a synonym for its AEDL Bronchogen record (CID 11690869); the ChemicalBook entry leaves the CAS field blank. Verify the identifier against the exact sequence and structure before procurement.

Note: Molecular formula and weight are theoretical values derived from amino-acid composition; they are not batch-specific assay results.

Molecular Identity: AEDL vs ADEL

A defining feature of Bronchogen's public record is that the amino-acid order is not uniformly reported:

  • AEDL (Ala-Glu-Asp-Leu): the sequence associated with the ChemicalBook commercial record (CB93358086) and current peptide-vendor listings.
  • ADEL (Ala-Asp-Glu-Leu): the sequence used in the peer-reviewed biophysical study by Monaselidze et al. (2011), which examined DNA thermostability.

These two sequences are not the same molecule. Glutamic acid and aspartic acid differ by one methylene group in their side chains; swapping their positions changes the peptide's three-dimensional arrangement, charge distribution and potential molecular interactions. Although AEDL and ADEL share the same nominal molecular formula and weight (they are constitutional sequence isomers), they must not be treated as interchangeable on a certificate of analysis. The available records do not establish that every commercial product sold as "Bronchogen" carries the same confirmed sequence.

This is why peptide identity cannot be inferred from the trade name alone. The full sequence must be confirmed against the supplier's documentation.

What Does the Research Show?

Published evidence on Bronchogen falls into three tiers, and buyers should distinguish them clearly.

  • Biophysical research. Monaselidze et al. (2011) used differential scanning microcalorimetry to study the effect of the ADEL peptide on DNA melting. In calf-thymus and mouse-liver DNA, Bronchogen increased the DNA melting temperature by approximately 3.1 °C within a narrow molar-ratio range, and the authors described it as a DNA-stabilizing agent rather than a sequence-specific A/T- or G/C-selective ligand.
  • Chromatin and plant-cell research. A separate line of work (Fedoreyeva et al., AIMS Biophysics, 2020) examined the AEDL peptide in relation to histone binding, chromatin conformation changes, and experiments in tobacco (plant) cells. These are mechanistic in vitro and plant-cell observations - not human or respiratory-cell research - and should not be read as evidence of activity in human airway tissue.
  • Clinical evidence limitations. Neither body of work establishes clinical efficacy in humans, and no large-scale human clinical trial should be assumed. Research teams have been relatively concentrated, and independent replication is limited. Bronchogen should be read as a research tool compound, not as a drug substance with an approved therapeutic indication.

Bronchogen vs. Chonluten

Bronchogen is sometimes discussed alongside Chonluten in the same short-peptide literature. They are not interchangeable:

Feature Bronchogen Chonluten
Peptide length Tetrapeptide (4 amino acids) Tripeptide (3 amino acids)
Reported sequence AEDL (commercial record) / ADEL (2011 study) Glu-Asp-Gly (EDG)
Nominal formula C₁₈H₃₀N₄O₉ (theoretical) C₁₁H₁₇N₃O₈
CAS status 857267-12-0 listed for the AEDL PubChem record; ChemicalBook field blank CAS 75007-24-8
Identity risk Sequence order disputed across sources Reported sequence: Glu-Asp-Gly (EDG); confirm against the delivered batch

Similar research themes do not make two peptides the same product. Ordering decisions should be based on the exact sequence on the COA, not on shared marketing categories.

Quality Verification in 2026

For a peptide with disputed identity, analytical documentation matters more than for a well-characterized API. Before ordering, buyers should require:

  1. Full sequence disclosure - AEDL or ADEL, stated explicitly on the COA.
  2. Identity confirmation - LC-MS or equivalent mass spectrometry matching the expected molecular species.
  3. Purity by HPLC - reported as chromatographic purity on a stated method and wavelength. Any stated purity value, including a 98% or higher specification, should be supported by the corresponding analytical report rather than assumed from the product name or general market listings.
  4. Batch traceability - lot number on the vial matching the certificate.
  5. Molecular weight cross-check - theoretical ~446.46 g/mol for either AEDL or ADEL.

HPLC purity confirms a chromatographic profile; it does not by itself prove sequence correctness or absolute peptide content. LC-MS confirms expected mass; it does not independently rule out every impurity.

B2B Research Supply Considerations

Buyers sourcing Bronchogen for laboratory or CRO use should establish:

  • The exact sequence their project requires (AEDL vs ADEL) - specified before purchase.
  • Whether the supplier can provide batch-specific HPLC and LC-MS documentation.
  • Storage conditions (typically desiccated, refrigerated or frozen per supplier specification).
  • Packaging, lead time, MOQ and temperature-controlled shipping options.
  • Whether third-party retesting is supported.

Contact HDM Biotech to confirm available specifications, sequence confirmation, batch documentation and research-use terms.

Conclusion

Bronchogen remains a research-grade short peptide whose public record is defined by sequence ambiguity rather than standardized chemical registration. In 2026, the responsible sourcing position is straightforward: confirm the exact sequence, require LC-MS identity matching, read HPLC purity against the batch-specific report, and do not extrapolate preclinical biophysical observations into clinical claims.

3

References

  • Monaselidze JR, Khavinson VK, Gorgoshidze MZ, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine. 2011;150(3):375-377. doi:10.1007/s10517-011-1146-x. PMID: 21240358.
  • Fedoreyeva LI, Vanyushin BF, Baranova EN. Peptide AEDL alters chromatin conformation via histone binding. AIMS Biophysics. 2020;7(1):1-16.
  • ChemicalBook. Bronchogen (Ala-Glu-Asp-Leu). CBNumber CB93358086. https://www.chemicalbook.com/ProductChemicalPropertiesCB93358086_EN.htm
  • PubChem. Bronchogen AEDL record, CID 11690869.
  • ChemicalBook. Chonluten CAS 75007-24-8 record. https://www.chemicalbook.com/CASEN_75007-24-8.htm

Send Inquiry

whatsapp

Phone

E-mail

Inquiry